Kathleen S. Wright Associates Inc. Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Kathleen S. Wright Associates Inc. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 462 shares of the medical equipment provider’s stock, valued at approximately $51,000.

A number of other large investors have also recently bought and sold shares of LNTH. Procyon Advisors LLC grew its position in shares of Lantheus by 16.0% during the third quarter. Procyon Advisors LLC now owns 3,252 shares of the medical equipment provider’s stock worth $357,000 after acquiring an additional 449 shares during the last quarter. Shaker Investments LLC OH increased its position in Lantheus by 60.5% in the 3rd quarter. Shaker Investments LLC OH now owns 44,803 shares of the medical equipment provider’s stock valued at $4,917,000 after acquiring an additional 16,886 shares during the period. Exchange Traded Concepts LLC raised its stake in Lantheus by 57.1% during the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider’s stock valued at $139,000 after acquiring an additional 460 shares in the last quarter. Juncture Wealth Strategies LLC grew its stake in shares of Lantheus by 6.0% in the third quarter. Juncture Wealth Strategies LLC now owns 11,248 shares of the medical equipment provider’s stock worth $1,234,000 after purchasing an additional 640 shares in the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the period. Institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 10,481 shares of Lantheus stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the sale, the director now owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the sale, the director now directly owns 454,923 shares of the company’s stock, valued at $43,445,146.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,981 shares of company stock worth $2,689,156 in the last 90 days. 1.50% of the stock is owned by company insiders.

Lantheus Stock Up 0.2 %

Lantheus stock traded up $0.21 during trading hours on Monday, hitting $112.40. The company had a trading volume of 128,615 shares, compared to its average volume of 979,379. The firm has a market capitalization of $7.79 billion, a P/E ratio of 17.13 and a beta of 0.50. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm’s fifty day moving average is $104.20 and its 200-day moving average is $89.50.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same period in the prior year, the firm earned $1.40 earnings per share. The business’s revenue was up 22.5% on a year-over-year basis. On average, research analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of research analyst reports. Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Leerink Partners lifted their price target on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. JMP Securities decreased their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Finally, B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average target price of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.